Ozempic / Mounjaro GI Injury (Gastroparesis & Bowel Obstruction) Products Liability MDL
Case Overview
Ozempic (semaglutide, made by Novo Nordisk) and Mounjaro (tirzepatide, made by Eli Lilly) belong to the class of GLP-1 receptor agonist drugs that have surged in popularity for weight loss and diabetes management. These medications work by slowing gastric emptying — a mechanism plaintiffs allege causes severe, sometimes permanent gastrointestinal conditions in a subset of users. Thousands of patients have filed suit alleging they developed gastroparesis (a condition in which the stomach cannot empty properly, causing chronic nausea, vomiting, and malnutrition), bowel obstruction, ileus, and other serious GI injuries after using these drugs. The MDL was established in the Eastern District of Pennsylvania in 2023 under Judge Gene Pratter.
Plaintiffs allege that Novo Nordisk and Eli Lilly knew or should have known of the elevated risk of severe gastrointestinal events and failed to adequately warn patients and prescribers. The cases argue the drug labels understated the severity and permanence of GI side effects, preventing informed consent. The litigation is closely watched as GLP-1 drugs have been prescribed to tens of millions of Americans. Discovery is ongoing, and bellwether trials — test cases designed to gauge jury reaction and guide settlement negotiations — are being selected. The litigation is separate from but related to psychiatric injury claims filed against Novo Nordisk in a different MDL.
Who May Qualify
Individuals who used Ozempic (semaglutide), Mounjaro (tirzepatide), Wegovy, Rybelsus, or other GLP-1 receptor agonist medications and were subsequently diagnosed with gastroparesis, bowel obstruction, intestinal ileus, or other serious gastrointestinal conditions. Both diabetic patients and those who used the drugs off-label for weight loss may qualify.
Frequently Asked Questions
Can I sue Novo Nordisk for gastroparesis caused by Ozempic?
If you were diagnosed with gastroparesis, bowel obstruction, or a similar serious GI condition after using Ozempic or a related GLP-1 drug, you may have a viable product liability claim. The MDL in Pennsylvania is actively accepting new cases. An attorney can review your medical records and prescription history to assess your claim.
What is the difference between the Ozempic gastroparesis lawsuit and the Ozempic suicidal ideation lawsuit?
These are two separate MDLs. MDL 3094 (Eastern District of Pennsylvania) covers gastrointestinal injuries like gastroparesis and bowel obstruction. A separate proceeding covers psychiatric injuries including suicidal ideation and depression. If you have both types of injuries, you may have claims in multiple proceedings.
Is there a settlement for the Ozempic gastroparesis lawsuit?
As of mid-2025, no settlement has been reached. The MDL is in active litigation and discovery phases. Bellwether trial selections are underway, and any settlement negotiations will likely follow initial trial results.
Related Cases
Social Media Addiction & Youth Mental Health School District MDL
Victoza (Liraglutide) Lawsuit: Vision Loss (NAION) Claims